SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-343820
Filing Date
2021-11-30
Accepted
2021-11-30 17:27:08
Documents
16
Period of Report
2021-11-29
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d217756d8k.htm   iXBRL 8-K 31340
2 EX-3.1 d217756dex31.htm EX-3.1 85712
3 EX-99.1 d217756dex991.htm EX-99.1 193565
4 EX-99.2 d217756dex992.htm EX-99.2 7022
8 GRAPHIC g217756g1129222916932.jpg GRAPHIC 2695
  Complete submission text file 0001193125-21-343820.txt   520604

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA rgls-20211129.xsd EX-101.SCH 2894
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgls-20211129_lab.xml EX-101.LAB 18889
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgls-20211129_pre.xml EX-101.PRE 11861
9 EXTRACTED XBRL INSTANCE DOCUMENT d217756d8k_htm.xml XML 3572
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

IRS No.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35670 | Film No.: 211460475
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences